Every claim on this page is borrowed. The cannabinoid literature on radiotherapy-induced nausea consists of three small trials, two British and one American, published between 1984 and 1987, each enrolling a few dozen patients, and all of them completed before ondansetron reached a single clinic. Nothing of substance has been added since. When a budtender or a wellness blog tells you edibles help with radiation sickness, what they mean, whether they know it or not, is that edibles help with chemotherapy nausea and radiation nausea looks similar enough.
That inference is defensible. It is still an inference, and this is the one page in our Oncology cluster where the honest answer to "does the science support this" is "the adjacent science does." We built the page anyway because radiotherapy patients ask, and the alternative is leaving the question to people who will answer it with a 25mg gummy and a shrug.
Why radiation makes you sick (and why it often doesn't)
Radiation nausea is a geography problem. The lining of the small bowel is dense with enterochromaffin cells that dump serotonin when irradiated, which fires the 5-HT3 receptors on the vagus nerve and lights up the vomiting center in the brainstem. That is the same pathway cisplatin uses, which is why the same drugs work. The MASCC/ESMO guideline sorts radiotherapy into four emetic risk tiers by target: total body irradiation at the top, upper abdomen and craniospinal fields in the moderate tier, brain, head and neck, chest and pelvis low, and breast or limbs so minimal that routine prophylaxis isn't recommended at all. Someone getting a breast boost does not need this page. Someone six weeks into upper abdominal fractions for a pancreatic tumor probably does.
The other difference from chemo is the calendar. Chemotherapy nausea arrives in cycles: a brutal week, then recovery, then the next infusion. Radiation is daily fractions, five days a week, for anywhere from one to seven weeks, and the nausea that comes with it tends to be lower grade and relentless rather than acute. A drug schedule built for a five-day chemo cycle does not transfer cleanly to that, and neither does an edible schedule.
One more carve-out. Nausea during brain radiation is usually about swelling and pressure inside the skull rather than serotonin in the gut. Dexamethasone treats that. An edible does not, and treating pressure nausea with THC is how people end up sedated and still vomiting.
What the three cannabinoid trials actually found
In 1984 the Priestmans, a husband-and-wife radiotherapy team in Britain, monitored 30 patients receiving wide-field upper abdominal irradiation. Fourteen never developed meaningful nausea. Ten were controlled by metoclopramide. The remaining six, who failed metoclopramide, all responded to nabilone (a synthetic THC analog that later got FDA approval for chemo nausea). Six for six is the kind of pilot result that gets a proper trial funded, and it did.
The proper trial came in 1987. Forty patients with radiation-induced emesis, double-blind, randomized, crossover, nabilone against metoclopramide. Result: no difference in efficacy, and the nabilone arm had significantly more adverse reactions, more often and more severe. Back in 1984, on the other side of the Atlantic, Ungerleider's UCLA group had compared oral THC against prochlorperazine in radiotherapy patients, had them rate nausea, mood, concentration and activity, then asked which drug they preferred. THC edged it, slightly.
Read together: cannabinoids performed roughly as well as the dopamine-antagonist antiemetics of the early 1980s, with more side effects when the cannabinoid was nabilone and a mild preference when it was THC itself. Then ondansetron arrived. A 1993 multicentre trial in upper abdominal radiotherapy gave a complete response in 61 percent of patients on ondansetron versus 35 percent on prochlorperazine, and the field moved on. Nobody went back to check whether a cannabinoid on top of a 5-HT3 antagonist added anything in radiotherapy. Nobody has checked since. The Grimison trial that anchors our chemotherapy page did exactly that experiment for chemo in 2024. Radiotherapy has no equivalent, and there is none registered.
Does the chemotherapy evidence carry over?
Partly, and the part that carries is the pharmacology. Cannabinoids suppress emesis through CB1 receptors in the dorsal vagal complex, downstream of the serotonin trigger. Parker's group has mapped this in detail, and the mechanism has no reason to care whether the serotonin was released by cisplatin or by daily fractions to the abdomen. The 2015 Cochrane review pooled 23 chemo trials and found patients on cannabinoids nearly six times more likely to report no vomiting at all than patients on placebo. Grimison's 2024 trial took 2.5mg THC with 2.5mg CBD, three times daily, and raised complete response from 8 percent to 24 percent in chemo patients who were still sick through dexamethasone, a 5-HT3 antagonist, and usually an NK-1 antagonist as well. That is the evidence people are borrowing when they recommend an edible for radiation nausea, and as borrowed evidence goes, it is good.
Three places the borrowing gets shaky. First, the radiotherapy trials that do exist showed parity with old antiemetics and a worse side effect profile, which is not the same shape of result as the chemo data. Second, duration. The trial dose of 7.5mg THC a day ran for five days per cycle. Six weeks of daily THC is a different exposure: tolerance builds, sedation accumulates, and a patient already flattened by treatment has less to spare. Third, there is no data of any kind on adding cannabinoids to ondansetron in radiotherapy patients, and that is the only combination anyone would use today.
The realistic reading is that a low-dose edible is a plausible add-on for someone whose nausea persists through guideline prophylaxis during abdominal or total body irradiation, and an unproven one. Both halves of that sentence are load-bearing.
What dose and timing make sense for daily fractions?
Mirror the antiemetic schedule, not the recreational one. Guidelines dose ondansetron before each fraction. A traditional edible needs 60 to 90 minutes to take hold, so the parallel is one low dose about an hour and a half before the daily appointment, which for most people is the same slot every weekday. Start at 2.5mg THC with matched CBD, which is half of a standard 5mg 1:1 gummy. On weekends and treatment breaks, when the fractions stop, the dosing stops too. That alone keeps cumulative exposure closer to what the trials tested and gives tolerance nowhere to build.
Skip three-times-daily dosing unless the nausea is continuous and your team agrees. Three doses a day for thirty treatment days is 225mg of THC across a course, taken by someone who was probably not a cannabis user before diagnosis, and no study anywhere has looked at that.
Fast-acting nano-emulsified products, the ones that kick in at 15 to 20 minutes, allow tighter timing and are worth considering if your nausea shows up within an hour or two of the fraction and a 90-minute lead time is impractical. Format matters more here than on most of our pages. Head and neck radiation causes mucositis, and a sour, citric-dusted gummy on an ulcerated mouth is its own small misery; a THC beverage or a soft chocolate goes down easier. (Head and neck is also low emetic risk, so most people in that group won't need this page for nausea in the first place.) The dispensary shelf is designed around Friday night. Nobody designs a gummy around a Tuesday 7:40am radiation appointment, so you will be adapting products that were never meant for this.
Drug interactions and disclosure
Disclosure is worse in radiotherapy than in medical oncology, for a mundane reason: radiation appointments are short, the radiation oncologist is often not the person managing your medication list, and patients assume a gummy is not worth mentioning to a technologist. It is. Ask for the nurse or the oncology pharmacist and say the dose in milligrams.
Where this page stops
No modern trial, no pediatric data, no long-course safety data, and the same cannabinoid hyperemesis caveat as every nausea page we publish: if you were a heavy daily user before diagnosis and your nausea reads as cyclical and resistant to everything, cannabis belongs on the suspect list.
The trial that would settle this would be cheap. A few hundred upper abdominal radiotherapy patients, ondansetron for everyone, 2.5mg THC and CBD or placebo before each fraction, six weeks. It will not be run, because radiotherapy nausea is a smaller and better-controlled problem than chemo nausea, and because nobody holds a patent on a 1:1 gummy that would pay for it. So this page will stay an inference page, probably permanently, and the most useful thing it can do is tell you that plainly and then show you how to borrow the chemo evidence with the least possible risk.